Dosing Regimen For Multiple Sclerosis
Patent No. EP3199172 (titled "Dosing Regimen For Multiple Sclerosis") was filed by Yeda Research on Aug 19, 2010. The application was issued on Jul 11, 2018.
Patent Summary
Reducing the frequency of subcutaneous glatiramer acetate injections from daily to three times a week for treating relapsing multiple sclerosis to improve tolerability without compromising efficacy. The lower frequency regimen is three injections over seven days with at least one day between each injection. This reduces post-injection reactions and improves patient compliance compared to daily injections.
Patent Family
Patent Oppositions (5)
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Get instant alerts for new documents
EP3199172
- Application Number
- EP17157735A
- Filing Date
- Aug 19, 2010
- Status
- Revoked
- May 10, 2024
- Publication Date
- Jul 11, 2018
- External Links
- Slate, Register , Google Patents